Sunitix Sunitinib 25 MG

Sunitix (Sunitinib) 25 MG

Price: $165.00

Sunitix (Sunitinib) helps to protect gastrointestinal stromal tumors (GIST; a type of tumor that grows in the stomach, intestine (bowel), or esophagus (tube that connects the throat with the stomach) in man and women with tumors that were not treated successfully with imatinib (Gleevec) or man and women who cannot take imatinib. Sunitix also helps to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the cells of the kidneys). Sunitinib further also helps to protect the return of RCC in people who have RCC that has not spread and have had a kidney removed. Sunitix further more helps to treat pancreatic neuroendocrine tumors (pNET, a type of tumor that begins in certain cells of the pancreas) in man and women with tumors that have worsened and cannot treat with surgery.

whatsapp
Whatsapp +8801922101029
Categories: , Tags: ,

Description

Sunitix (Sunitinib) Tablets is an anti-cancer medication. It blocks the action of the abnormal protein that signals cancer cells to multiply. This prevent to stop or slow the spread of cancer cells.

Indications Sunitix

Gastrointestinal Stromal Tumor (GIST): It indicate for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.

Advanced Renal Cell Carcinoma (RCC): This indicate for the treatment of advanced renal cell carcinoma.

Advanced Pancreatic Neuroendocrine Tumors (pNET): Sunitix indicate for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease.

Pharmacology

Sunitix (Sunitinib) inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs).

These include all receptors for platelet-derived growth factor (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs). which play a role in both tumor angiogenesis and tumor cell proliferation. The simultaneous inhibition of these targets. Therefore reduces tumor vascularization and triggers cancer cell apoptosis and thus results in tumor shrinkage.

Sunitinib also inhibits CD117 (c-KIT), the receptor tyrosine kinase that (when improperly activated by mutation) drives the majority of gastrointestinal stromal cell tumors. It has been recommended as a second-line therapy for patients whose tumors develop mutations in c-KIT that make them resistant to imatinib, or who the cannot tolerate the drug.

In addition, Sunitinib binds other receptors. These include: RET, CD114, CD135. The fact that Sunitix targets many different receptors. Leads to many of its side effects such as the classic hand-foot syndrome, stomatitis, and other dermatologic toxicities.

Dosage & Administration

Recommended Dose For GIST And RCC: The recommended dose of medicine for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is one 50 mg oral dose need to take once daily. On a schedule of 4 weeks on treatment follow by 2 weeks off (Schedule 4/2). Sunitix (Sunitinib) take to with or without food.

Recommended Dose For pNET: The recommended dose of Capsule  for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily continuously without a scheduled off-treatment period.

Dose Modification: Dose interruption and/or dose modification in 12.5 mg increments or decrements recommend based on individual safety and tolerability. The maximum dose administered in the Phase 3 pNET study was 50 mg daily.

Alternate concomitant medication with no or minimal enzyme inhibition potential is recommended. A dose reduction to a minimum of 37.5 mg (GIST and RCC) or 25 mg (pNET). Daily consider as Sunitix must co-administer with a strong CYP3A4 inhibitor

Selection of an alternate concomitant medication with no or minimal enzyme induction potential recommend. A dose increase for Sunitix  to a maximum of 87.5 mg (GIST and RCC) or 62.5 mg (pNET) daily consider if Sunitix must co-administer with a CYP3A4 inducer. If dose increase, the patient monitor carefully for toxicity.

Interaction

Increased plasma cone with strong CYP3A4 inhibitors (eg ketoconazole, ritonavir, itraconazole, erythromycin, clarithromycin, grapefruit juice). Decreased plasma cone with strong CYP3A4 inducers [eg rifampin, dexamethasone, phenytoin, carbamazepine, phenobarb, St. John’s wort (Hypericum perforatum)]. Anticoagulants eg warfarin, acenocoumarol (periodically monitor platelets, prothrombin time/INR & physical exam).

Side Effects

Common side effects of Sunitix (Sunitinib) include:

  • tiredness
  • weakness
  • diarrhea
  • pain, swelling or sores inside of your mouth
  • nausea
  • loss of appetite
  • indigestion
  • vomiting
  • stomach-area (abdominal) pain
  • blisters or rash on the palms of your hands and soles of your feet
  • high blood pressure
  • taste changes
  • low platelet counts

Pregnancy & Lactation

Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction. From data investigational or marketing experience or studies in humans. But potential benefits may warrant use of the drug in pregnant women despite potential risks.
For any inquiries please contact us
For more Urology medicine, visit our SHOP

No images in this gallery yet!

Reviews

There are no reviews yet.

Be the first to review “Sunitix (Sunitinib) 25 MG”

Your email address will not be published. Required fields are marked *